Skip to main content
SpringerLink
Log in

Epidemiology of atherosclerosis in systemic lupus erythematosus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Patients with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic coronary events. Traditional risk factors, such as hypertension and hypercholesterolemia, only partly account for the increased risk of coronary disease in SLE. Other important risk factors include disease and treatmentrelated factors. Novel markers of coronary risk in SLE are being investigated. Several methods have been used to detect subclinical atherosclerosis in patients with SLE. Among these, scintigraphic myocardial perfusion defects have been shown to be predictive of subsequent coronary events, independent of traditional Framingham risk factors. Although the aggressive treatment of reversible risk factors, such as lipids and blood pressure, is advocated by many, no published studies have yet demonstrated a clear reduction in risk of coronary events with this approach. Elucidation of risk factors and preventive strategies for accelerated atherosclerosis in SLE is the subject of ongoing research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gladman DD, Urowitz MB: Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987, 14(Suppl 13):223–226.

    PubMed  Google Scholar 

  2. Rubin LA, Urowitz MB, Gladman DD: Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985, 55:87–98.

    PubMed  CAS  Google Scholar 

  3. Urowitz MB, Bookman AA, Koehler BE, et al.: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60:221–225.

    Article  PubMed  CAS  Google Scholar 

  4. Urowitz MB, Ibanez D, Gladman DD: Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007, 34:70–75.

    PubMed  Google Scholar 

  5. Manzi S, Meilahn EN, Rairie JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408–415.

    PubMed  CAS  Google Scholar 

  6. Petri M, Perez-Gutthann S, Spence D, Hochberg MC: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93:513–519.

    Article  PubMed  CAS  Google Scholar 

  7. Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26:257–278.

    Article  PubMed  CAS  Google Scholar 

  8. Adams RJ, Chimowitz MI, Alpert JS, et al.: Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003, 108:1278–1290.

    Article  PubMed  Google Scholar 

  9. Manzi S, Selzer F, Sutton-Tyrrell K, et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51–60.

    Article  PubMed  CAS  Google Scholar 

  10. Roman MJ, Shanker BA, Davis A, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399–2406.

    Article  PubMed  CAS  Google Scholar 

  11. Rahman P, Urowitz MB, Gladman DD, et al.: Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999, 26:2363–2368.

    PubMed  CAS  Google Scholar 

  12. Bruce IN, Urowitz MB, Gladman DD, et al.: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48:3159–3167.

    Article  PubMed  Google Scholar 

  13. Esdaile JM, Abrahamowicz M, Grodzicky T, et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331–2337.

    Article  PubMed  CAS  Google Scholar 

  14. Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137–2143.

    PubMed  CAS  Google Scholar 

  15. Rahman P, Aguero S, Gladman DD, et al.: Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000, 9:672–675.

    Article  PubMed  CAS  Google Scholar 

  16. Asia Pacific Cohort Studies Collaboration: Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005, 112:3384–3390.

    Article  Google Scholar 

  17. Bostom AG, Rosenberg IH, Silbershatz H, et al.: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999, 131:352–355.

    PubMed  CAS  Google Scholar 

  18. Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877–881.

    Article  PubMed  CAS  Google Scholar 

  19. Petri M, Roubenoff R, Dallal GE, et al.: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996, 348:1120–1124.

    Article  PubMed  CAS  Google Scholar 

  20. Roman MJ, Crow MK, Lockshin MD, et al.: Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412–3419.

    Article  PubMed  CAS  Google Scholar 

  21. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  22. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363–369.

    Article  PubMed  Google Scholar 

  23. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.

    Article  PubMed  Google Scholar 

  24. Lee SS, Singh S, Link K, Petri M: High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008, 38:41–54.

    Article  PubMed  CAS  Google Scholar 

  25. Kiani AN, Magder L, Petri M: Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35:1300–1306.

    PubMed  CAS  Google Scholar 

  26. Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al.: Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001, 37:1075–1082.

    PubMed  CAS  Google Scholar 

  27. Doria A, Shoenfeld Y, Wu R, et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071–1077.

    Article  PubMed  CAS  Google Scholar 

  28. Toloza SM, Uribe AG, McGwin G Jr, et al.: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947–3957.

    Article  PubMed  Google Scholar 

  29. Ibanez D, Gladman DD, Urowitz MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005, 32:824–827.

    PubMed  Google Scholar 

  30. Karp I, Abrahamowicz M, Fortin PR, et al.: Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008, 59:169–175.

    Article  PubMed  CAS  Google Scholar 

  31. Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254–259.

    Article  PubMed  CAS  Google Scholar 

  32. Sachet JC, Borba EF, Bonfa E, et al.: Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16:273–278.

    Article  PubMed  CAS  Google Scholar 

  33. Wallace DJ, Metzger AL, Stecher VJ, et al.: Cholesterollowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322–326.

    Article  PubMed  CAS  Google Scholar 

  34. Rahman P, Gladman DD, Urowitz MB, et al.: The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325–330.

    PubMed  CAS  Google Scholar 

  35. Johansson E, Forsberg K, Johnsson H: Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981, 10:89–96.

    PubMed  CAS  Google Scholar 

  36. Petri M, Yoo S-S: Predictors of glucose intolerance in systemic lupus erythematosus. Arthritis Rheum 1994, 37:S323.

    Google Scholar 

  37. Sherer Y, Shoenfeld Y: Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003, 207:13–16.

    Article  PubMed  CAS  Google Scholar 

  38. Ahmad Y, Shelmerdine J, Bodill H, et al.: Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007, 46:983–988.

    Article  CAS  Google Scholar 

  39. Nikpour M, Urowitz MB, Gladman DD: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005, 31:329–354, vii–viii.

    Article  PubMed  Google Scholar 

  40. O’Leary DH, Polak JF, Kronmal RA, et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999, 340:14–22.

    Article  PubMed  Google Scholar 

  41. van der Meer IM, Bots ML, Hofman A, et al.: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004, 109:1089–1094.

    Article  PubMed  Google Scholar 

  42. Nallamothu BK, Saint S, Bielak LF, et al.: Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med 2001, 161:833–838.

    Article  PubMed  CAS  Google Scholar 

  43. Asanuma Y, Oeser A, Shintani AK, et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407–2415.

    Article  PubMed  CAS  Google Scholar 

  44. Hosenpud JD, Montanaro A, Hart MV, et al.: Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984, 77:286–292.

    Article  PubMed  CAS  Google Scholar 

  45. Nikpour M, Gladman DD, Ibanez D, et al.: Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:288–294.

    Article  PubMed  Google Scholar 

  46. Bruce IN: ’Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1492–1502.

    Article  CAS  Google Scholar 

  47. Wajed J, Ahmad Y, Durrington PN, Bruce IN: Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. Rheumatology (Oxford) 2004, 43:7–12.

    Article  CAS  Google Scholar 

  48. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  49. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  50. Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Toronto Western Hospital, University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada

    Murray B. Urowitz

Authors
  1. Mandana Nikpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murray B. Urowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dafna D. Gladman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murray B. Urowitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nikpour, M., Urowitz, M.B. & Gladman, D.D. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep 11, 248–254 (2009). https://doi.org/10.1007/s11926-009-0035-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0035-z

Keywords

Search

Navigation